1. Home
  2. COCH vs CNTX Comparison

COCH vs CNTX Comparison

Compare COCH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.70

Market Cap

49.7M

Sector

Finance

ML Signal

HOLD

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCH
CNTX
Founded
1995
2015
Country
United States
United States
Employees
47
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.7M
51.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
COCH
CNTX
Price
$0.70
$0.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$6.00
$6.60
AVG Volume (30 Days)
738.0K
5.0M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.55
52 Week High
$1.89
$3.62

Technical Indicators

Market Signals
Indicator
COCH
CNTX
Relative Strength Index (RSI) 48.72 30.98
Support Level $0.64 $0.55
Resistance Level $0.74 $1.26
Average True Range (ATR) 0.09 0.07
MACD 0.00 0.06
Stochastic Oscillator 22.33 64.54

Price Performance

Historical Comparison
COCH
CNTX

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: